12/4
01:28 pm
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
12/4
09:00 am
vnrx
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
Medium
Report
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
12/3
02:19 pm
vnrx
VolitionRx (NYSE:VNRX) had its "hold" rating reaffirmed by analysts at Maxim Group.
Low
Report
VolitionRx (NYSE:VNRX) had its "hold" rating reaffirmed by analysts at Maxim Group.
11/26
12:56 pm
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
11/25
09:10 am
vnrx
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use [Yahoo! Finance]
Low
Report
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use [Yahoo! Finance]
11/25
08:45 am
vnrx
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
High
Report
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
11/17
12:01 pm
vnrx
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at HC Wainwright from $2.50 to $1.50. They now have a "buy" rating on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at HC Wainwright from $2.50 to $1.50. They now have a "buy" rating on the stock.
11/17
08:20 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
11/14
12:54 pm
vnrx
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
08:45 am
vnrx
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
Low
Report
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
10/17
08:00 am
vnrx
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
Medium
Report
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
10/10
08:30 am
vnrx
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
Medium
Report
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
10/9
04:28 pm
vnrx
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants [Yahoo! Finance]
Medium
Report
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants [Yahoo! Finance]
10/9
04:05 pm
vnrx
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
High
Report
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
10/2
09:01 am
vnrx
Volition Sponsors Upcoming GenomeWeb Webinar [Yahoo! Finance]
Low
Report
Volition Sponsors Upcoming GenomeWeb Webinar [Yahoo! Finance]
10/2
08:45 am
vnrx
Volition Sponsors Upcoming GenomeWeb Webinar
Low
Report
Volition Sponsors Upcoming GenomeWeb Webinar
10/1
08:06 pm
vnrx
VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode. [Yahoo! Finance]
Low
Report
VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode. [Yahoo! Finance]
9/30
08:06 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Medium
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
9/29
12:52 pm
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
9/29
09:30 am
vnrx
Volition Signs Co-Marketing and Services Agreement with Hologic
Low
Report
Volition Signs Co-Marketing and Services Agreement with Hologic
9/18
09:59 am
vnrx
Epigenetics Market Size Drives at 15.32% CAGR to Reach USD 70.51 Billion by 2034 [Yahoo! Finance]
Medium
Report
Epigenetics Market Size Drives at 15.32% CAGR to Reach USD 70.51 Billion by 2034 [Yahoo! Finance]
9/10
08:00 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
9/9
08:56 am
vnrx
Volition Signs First Human Out Licensing Deal [Yahoo! Finance]
Low
Report
Volition Signs First Human Out Licensing Deal [Yahoo! Finance]
9/9
08:45 am
vnrx
Volition Signs First Human Out Licensing Deal
Low
Report
Volition Signs First Human Out Licensing Deal